Published: Tuesday, May 24, 2022
The American Herbal Products Association (AHPA) has offered feedback on mandatory product listing (MPL) provisions included in a recently released “discussion draft” of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, a piece of must-pass legislation that reauthorizes drug and medical device user fee programs. The draft had been released by the United States Senate Committee on Health, Education, Labor and Pensions (HELP) last week.
AHPA’s feedback reiterates the association’s position of opposition to MPL on the grounds that it is unnecessary, redundant to existing U.S. Food and Drug Administration (FDA) authority, unlikely to address any clear regulatory need, and will reduce access to safe and lawful dietary supplements. In the event that an MPL requirement is established, AHPA further proposes extensive changes that would minimize its burdens, and outlines several alternate revisions to the Federal Food, Drug and Cosmetic Act that would more meaningfully advance the health of American citizens by providing better education for and access to safe dietary supplements.
AHPA’s full feedback on the discussion draft is available here.
2022 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.